1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2000
-------------
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD From_________________
to __________________
Commission File number 0-935
AMPERSAND MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 36-4296006
------------------------------------- --------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
414 N. Orleans Street, Suite 510
Chicago, IL 60610
--------------------------------------------
(Address of principal executive offices)
(Zip Code)
(312) 222-9550
--------------
(Registrant's telephone number, including area code)
414 N. Orleans Street, Suite 305, Chicago, IL 60610
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter periods that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13, or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by the court. Yes No
----- ----
APPLICABLE ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date.
Common Stock, $0.001 par value per share-----29,959,135 shares as of August
11, 2000
1
2
INDEX
AMPERSAND MEDICAL CORPORATION AND SUBSIDIARIES
Part I. Financial Information
Item 1. Financial Statements (Unaudited)
Consolidated Balance Sheets - June 30, 2000 and December 31,
1999
Consolidated Statements of Operations -- Six months ended June
30, 2000 and June 30, 1999 and three months ended June 30,
2000 and June 30, 1999
Consolidated Statements of Cash flows -- Six months ended June
30, 2000 and June 30, 1999
Notes to consolidated financial statements - June 30, 2000
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations
Item 3. Quantitative and Qualitative Disclosure of Market Risk
Part II. Other Information
Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 3. Defaults on Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
2
3
Part I. Financial Information
Item 1 Financial Statements
Ampersand Medical Corporation and Subsidiaries
(Formerly Bell National Corporation)
Consolidated Balance Sheets
(Dollars in thousands, except per share amounts)
June 30, December 31,
2000 1999
(Unaudited)
----------- ------------
ASSETS
Current assets:
Cash and cash equivalents $ 56 $ 36
Accounts receivable, net of allowance of $ 21 325 398
Note receivable - related party 1,800 -
Inventories 204 62
Refundable taxes 106 131
Deposits 160 -
Prepaid expenses 96 54
--------- ---------
Total current assets 2,747 681
Fixed assets, net 280 177
Other assets:
Prepaid royalties 1,020 -
License, patent, and technology, net of amortization 679 696
Goodwill, net 225 317
--------- ---------
Total assets $ 4,951 $ 1,871
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ 939 $ 1,449
Customer deposits 46 40
Accrued payroll costs 175 450
Accrued royalties - 250
Accrued expenses 323 399
Deferred revenue 83 68
Revolving line of credit 58 134
Current maturities of notes payable - related party - 125
Current maturities of notes payable 175 970
--------- ---------
Total current liabilities 1,799 3,885
--------- ---------
Notes payable - related party, less current maturities - 26
Stockholders' Equity (deficit)
Common stock, $0.001 par value;
Authorized 50,000,000
Issued and outstanding, 29,959,135 shares
at June 30, 2000, 19,027,570 shares at 30 19
December 31, 1999
Additional paid in capital 12,054 3,039
Accumulated deficit (8,800) (5,015)
Accumulated comprehensive loss -
Cumulative translation adjustment (132) (83)
--------- ---------
Total stockholder's equity (deficit) 3,152 (2,040)
--------- ---------
Total liabilities and stockholders' equity (deficit) $ 4,951 $ 1,871
========= =========
The accompanying notes are an integral part of these consolidated financial statements
3
4
Ampersand Medical Corporation and Subsidiaries
(Formerly Bell National Corporation)
Consolidated Statements of Operations
(Unaudited)
(Dollars in thousands, except for per share amounts)
Six Months Three Months
Ended June 30, Ended June 30,
2000 1999 2000 1999
------------- ------------- ------------ -------------
Net Sales $ 541 $ 542 $ 179 $ 231
Cost and expenses
Cost of goods sold 349 311 159 154
Research and development expenses 1,319 514 513 289
Selling, general and administrative expenses 2,654 1,023 171 559
------------- ------------- ------------ -------------
4,322 1,848 843 1,002
------------- ------------- ------------ -------------
Operating loss (3,781) (1,306) (664) (771)
Other income (expense)
Interest income 27 - 27 -
Interest (expense) - related party (2) (17) (1) (8)
Interest (expense) (28) (14) (8) (14)
Other, net (1) (1) - (2)
------------- ------------- ------------ -------------
(4) (32) 18 (24)
------------- ------------- ------------ -------------
Loss before income taxes (3,785) (1,338) (646) (795)
Income taxes - - - -
------------- ------------- ------------ -------------
Net loss $ (3,785) $ (1,338) $ (646) $ (795)
============= ============= ============ =============
Basic and fully diluted net loss
per common share $ (0.15) $ (0.11) $ (0.02) $ (0.06)
============= ============= ============ =============
Weighted average number of
common shares outstanding 25,582,805 12,365,000 29,865,088 12,638,750
============= ============= ============ =============
The accompanying notes are an integral part of these consolidated financial statements.
4
5
Ampersand Medical Corporation
(Formerly Bell National Corporation)
Consolidated Statement of Cash Flows
(Unaudited)
(Dollars in thousands)
Six Months Six Months
Ended Ended
June 30, 2000 June 30, 1999
------------- -------------
Operating activities:
Net loss $ (3,785) $ (1,338)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 142 82
Interest expense paid with stock 25
Stock, warrants, and options issued
to non-employees for services 271 -
Compensation expense related to
stock appreciation rights 1,266 -
Changes in assets and liabilities
Accounts receivable 73 (191)
Notes receivable (1,800) -
Inventories (142) (96)
Prepaid royalties (500) -
Deposits, prepaids and other assets (193) (167)
Accounts payable (510) 349
Customer deposits 6 89
Accrued royalties (250) -
Deferred revenue 15 29
Accrued expenses (249) 242
-------- --------
Net cash used in operating activities (5,631) (1,001)
Cash used in investing activities
Expenditure for license, patent
and technology (22) (497)
Purchase of fixed assets (139) (61)
-------- --------
Net cash used in investing activities (161) (558)
Cash flows from financing activities
Proceeds from issuance of
convertible notes - 970
Proceeds from revolving line of
credit, net of payments (76) -
Payment of notes payable - related party (26) (1)
Proceeds from issuance of common stock,
net of costs incurred 5,963 28
-------- --------
Net cash provided by financing activities 5,861 997
Effect of exchange rate changes on cash (49) (78)
-------- --------
Net increase (decrease) in cash and cash
equivalents 20 (640)
Cash and cash equivalents at beginning of period 36 700
Cash and cash equivalents at end of period $ 56 $ 60
======== ========
Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest $ 3 $ -
======== ========
The accompanying notes are an integral part of these consolidated financial statements
5
6
AMPERSAND MEDICAL CORPORATION AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Unaudited June 30, 2000)
NOTE A. BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the six-month period ended June 30, 2000
are not necessarily indicative of the results that may be expected for the year
ended December 31, 2000.
The balance sheet at December 31, 1999 has been derived from the audited
financial statements at that date but does not include all of the information
and footnotes required by generally accepted accounting principles for complete
financial statements.
For further information, refer to the consolidated financial statements and
footnotes thereto included in the Ampersand Medical Corporation and
Subsidiaries' annual report on Form 10-K for the year ended December 31, 1999.
NOTE B. OVERVIEW
Ampersand Medical Corporation ("Ampersand" and together with its subsidiaries
the "Company") was incorporated in Delaware on December 15, 1998, as a wholly
owned subsidiary of Bell National Corporation. At the Annual Meeting of Bell
National on May 25, 1999, the stockholders approved the merger of Bell National
into Ampersand. The merger was affected on May 26, 1999 and Bell National ceased
its existence. At the Annual Meeting, the stockholders also approved an increase
in the authorized shares of Common Stock of the Company from 20,000,000 to
50,000,000 shares.
From a historical perspective prior to its merger into Ampersand, Bell National
Corporation ("Bell National") was incorporated in California on October 1, 1958.
Through 1985, its principal subsidiary was Bell Savings and Loan Association
("Bell Savings"), a state chartered savings and loan association. On July 25,
1985, the Federal Home Loan Bank Board appointed the Federal Savings & Loan
Insurance Corporation ("FSLIC") as receiver of Bell Savings. At the same time,
the assets of Bell Savings were transferred to a new, unrelated, federally
chartered mutual savings and loan association, Bell Federal. The FSLIC's action
followed shortly after a determination that Bell Savings had a negative net
worth. On August 20, 1985, Bell National filed a voluntary petition under
Chapter 11 of the Bankruptcy Code. A plan of reorganization was approved by the
Bankruptcy Court, and became effective June 29, 1987.
On June 15, 1990, Bell National purchased 100% of the Common Stock of Payne
Fabrics, Inc., a designer and distributor of decorative drapery and upholstery
fabrics, for a purchase price of $6,493,000 and the issuance of stock
appreciation rights. On August 4, 1997 Payne Fabrics, Inc. sold substantially
all of its assets and most of its liabilities related to the business of
designing and distributing decorative drapery and upholstery fabrics to Westgate
Fabrics, Inc. ("Westgate"), an unaffiliated third party (the "Asset Sale"). The
Asset Sale included the transfer to the buyer of the use and rights to the Payne
Fabrics name, accordingly, Payne Fabrics, Inc., changed its name to PFI National
Corporation ("PFI"). The Asset Sale left PFI without any substantial assets and
on August 4, 1997 all operations were ceased. Bell National's other wholly owned
subsidiaries, Bell Savings and Pacific Coast Holdings Insurance Company, had no
significant assets or liabilities. After the Asset Sale and before December
1998, the Company had no business operations and its only activities were
administrative.
6
7
On December 4, 1998, Bell National acquired InPath, LLC, a development-stage
company engaged in the design and development of medical instruments and related
tests. In the acquisition, Bell National issued 4,288,790 shares of Common Stock
and warrants to purchase 3,175,850 shares of Common Stock to the members of
InPath in exchange for their units of membership interest in InPath and the
senior executives of InPath assumed management control of Bell National.
Subsequent to the Annual Meeting of the stockholders on May 25, 1999, all of the
warrants were exercised and exchanged for shares of Common Stock in the company.
Based upon the terms of the acquisition agreement, for financial reporting and
accounting purposes the acquisition has been accounted for as a reverse
acquisition whereby InPath is deemed to have acquired Bell National. However,
Bell National was the continuing legal entity and registrant for both Securities
and Exchange Commission filing purposes and income tax filing purposes, until
its merger into Ampersand in May 1999. Because Bell National was a non-operating
public shell company with nominal assets and InPath was a private operating
company, the acquisition has been recorded as the issuance of stock for the net
monetary assets of Bell National, accompanied by a recapitalization and no
goodwill or other intangible assets were recorded
In December 1998, the Company formed a French limited liability company
subsidiary, Samba Technologies, Sarl ("Samba"), for the purpose of acquiring the
automated image cytometry and tele-medicine technology used in the business of
the Samba department of Unilog Regions, SA, a French company engaged in the
design, development and installation of commercial software programs and
networks for business application. Samba completed the acquisition of the
department's assets on January 4, 1999, and at the same time entered into
employment arrangements with the former department employees and assumed the
day-to-day operations. Since the acquisition, Samba has continued to develop and
market the image cytometry and tele-medicine products previously developed and
marketed by the department.
The Company has incurred significant net losses since its inception. The Company
expects that significant on-going operating expenditures will be necessary to
successfully implement its business plan and develop, manufacture and market its
products. These circumstances raise substantial doubt about the Company's
ability to implement its business plan and continue as a going concern.
Management's plans include continuing efforts to obtain additional capital.
During the first six months of 2000, the Company successfully raised
approximately $5,963,000 to finance its operations. In addition, the holder of a
Senior Subordinated Note converted the $50,000 principal and $1,250 in accrued
interest due thereon into shares of Common Stock thus reducing the Company's
outstanding liabilities. On April 28, 2000 the Company automatically converted
$969,600 of 6% Convertible Subordinated Notes Due 2000 plus approximately
$61,658 in accrued interest due thereon into Common Stock also reducing the
Company's outstanding liabilities. However, there can be no assurance that the
Company will continue to be successful in raising capital should the need for
such capital arise in the future. If the Company is unable to obtain additional
financing, should the need arise, or generate profitable sales revenues,
management may be required to curtail the Company's product development and
other activities and may be forced to cease operations.
NOTE C. NOTE RECEIVABLE - RELATED PARTY
On April 28, 2000 the Company sold 1,333,333 shares of Common Stock at $1.50 per
share for total proceeds of $2,000,000, to Seaside Partners, LP, a hedge fund
which receives investment management services from Seaside Advisor, L.L.C., of
which Dr. Denis O'Donnell, a director of the Company, is a member and manager,
as part of the January 2000 Private Placement Offering. In lieu of cash, the
Company agreed to accept payment for the stock in the form of a $2,000,000
Promissory Note (the"Note"). The Note was due July 27, 2000 and bears interest
at the rate of 8% per annum. The Note may be prepaid in part or in full without
penalty, and the due date may be extended by mutual consent of both parties. In
addition the Company retains possession of the stock certificates representing
the purchased shares until the Note is paid in full. The Subscription Agreement
under which the shares were purchased and the related promise to pay shall not
be voidable or cancelable for any reason or circumstance whatsoever. During June
2000, Seaside made two partial principal payments against the Note of $100,000.
Additional partial
7
8
principal payments of $450,000 were received during the month of July 2000, and
the Company agreed to extend the term of the remaining Note balance for an
additional term of 30 days to August 26, 2000.
NOTE D. PREPAID ROYALTIES
On June 9, 2000 the Company and AccuMed International, Inc. signed an Amendment
to a Patent and Technology License Agreement dated September 4, 1998. Under the
Amendment the Company paid AccuMed $500,000 in cash, agreed to issue a
Convertible Promissory Note, effective June 9, 2000, in the principal amount of
$100,000 and authorized its transfer agent to issue 128,571 shares of Common
Stock to AccuMed. The Amendment characterizes the $500,000 cash payment, the
$100,000 principal amount of the note (see Note F below), and the fair value of
the Common Stock up to a maximum of $450,000, or $3.50 per share, as
non-refundable advance royalty payments. The Company had previously recorded a
liability and related expense for minimum royalty payments due under the
original License totaling $500,000, which was reclassified to prepaid royalties
in accordance with the Amendment. The Company recorded a fair value of $385,713
for the shares issued. Under the Amendment, the Company has agreed to price
protect the shares up to the maximum fair value level provided. The Company
recorded a liability of $64,287 to reflect the potential cost of the price
protection guarantee as of the date of issuance of the shares.
NOTE E. NOTES PAYABLE - RELATED PARTIES
On September 1, 1998 the Company issued a note payable in the amount of $175,000
to Mr. Peter P. Gombrich, its Chairman and CEO, in payment for funds advanced to
the Company. Principal payments in the amount of $130,000 and $19,000 were made
during 1999 and 1998 respectively. The remaining principal balance of $26,000
plus $15,600 in accrued interest over the entire life of the note was repaid
during the first quarter of 2000.
On May 11, 1999 the Company borrowed $75,000 under a 6% Convertible Subordinated
Note to Leonard R. Prange, President, COO/CFO. The Note was issued under terms
identical to all 6% Convertible Subordinated Notes issued by the Company. The
Note plus accrued interest due thereon was automatically converted into Common
Stock of the Company on April 28, 2000.
On December 10, 1999 the Company borrowed $50,000 from Azimuth Corporation, a
company controlled by Alexander M. Milley, a director and significant
shareholder of the Company, under a convertible senior subordinated promissory
note. On February 22, 2000 Azimuth Corporation exercised its right to convert
the principal amount of the note plus accrued interest due thereon in the amount
of $1,250 into 256,250 shares of Common Stock of the Company.
NOTE F. NOTES PAYABLE
On August 28, 1998, the Company issued a note payable in the amount of $75,000
to its former outside legal counsel, Holleb & Coff in payment for legal
services. The note is due on demand and interest accrues monthly at the rate of
12% per annum. The outstanding balance, plus accrued interest at June 30, 2000
is $91,500.
In January 1999, the Board of Directors authorized the Company to raise up to
$1,500,000 in new equity or debt to provide funding for current operations.
Subsequently, on various dates between March 1, 1999 and June 29, 1999, the
Company issued a series of interest bearing 6% Convertible Promissory Notes
totaling $969,600, including a Note in the amount of $500,000 issued to Seaside
Partners, L.P., a hedge fund which receives investment management services from
Seaside Advisors, L.L.C., of which Dr. Denis M. O'Donnell, a director of the
Company, is a member and manager, and a Note in the amount of $75,000 issued to
Leonard R. Prange, President, COO/CFO (see Note E above), in exchange for cash.
The maturity date of the Notes was January 28, 2000, subject to extension by the
Company to June 30, 2000. On January 25, 2000, the Company notified the note
holders that it was extending the maturity date of the Notes until June 30,
2000. On April 28, 2000 the Notes plus accrued interest due thereon were
automatically converted into shares of Common Stock.
8
9
In July 1999, the Company's wholly owned subsidiary, Samba, negotiated a
Revolving Credit Line ("Revolver") with the Banc National de Paris (BNP). The
terms of the Revolver provide that Samba may borrow, in the form of an advance
on payment against monthly billings, up to a maximum of 900,000 French Francs,
approximately $140,000. The terms of the Revolver require Samba to pay interest
at Euribor plus 2.5%, (currently equal to 7.65%) on advances outstanding under
the Revolver and grant BNP a security interest in Samba accounts receivable. The
Revolver was renewed for an additional twelve months in June 2000. As of June
30, 2000 the amount outstanding under the Revolver was approximately $58,000.
On June 9, 2000, the Company agreed to issue a convertible promissory note,
effective June 9, 2000, to AccuMed International, Inc. The note, which is due on
March 29, 2001, has a principal amount of $100,000, bears interest at the rate
of 11%, and is convertible, at the option of AccuMed, into Common Stock of the
Company at the rate of $3.50 per share. The note was issued in conjunction with
an Amendment to a Patent and Technology License Agreement between the Company
and AccuMed (dated September 4, 1998) dated June 9, 2000. The License Amendment
specifies that the principal amount of the note shall be characterized as a
prepaid royalty payment (see Note D above).
NOTE G. STOCKHOLDERS EQUITY
During January 2000, upon receipt of cleared funds received under a 1999 Private
Placement Offering, the Company completed the sale of 1,712,120 shares of Common
Stock for total gross proceeds of $565,000.
In January 2000, the Board of Directors authorized the Company to raise a
minimum of $5,000,000 in new equity, at a price of $1.50 per share. Between
February 7, 2000 and April 30, 2000, the closing date, the Company sold
3,583,333 shares of Common Stock for total proceeds of $5,375,000 under this
Private Placement Offering.
The 6% Convertible Subordinated Notes issued by the Company during 1999
contained a clause which provided for the automatic conversion of the Notes plus
any accrued interest due thereon into Common Stock of the Company when a minimum
requirement of $5,000,000 in new equity was met. On April 28, 2000, the Company
reached the minimum new equity requirement as a result of the above mentioned
Private Placement Offering. Accordingly, on that date the Notes, including
$969,600 of principal and $61,658 of accrued interest due thereon, were
automatically converted into 5,156,294 shares of Common Stock at a conversion
price of $0.20 per share. The conversion price was computed in accordance with
the provisions of the Notes and represented an adjustment of the original
conversion price.
On February 22, 2000 Azimuth Corporation exercised its right to convert the
$50,000 principal amount of a Note plus $1,250 in accrued interest due thereon
into 256,250 shares of Common Stock of the Company, at a conversion price of
$0.20 per share.
On April 10, 2000 the Company received $23,100 to exercise a warrant held by The
Research Works to purchase 70,000 of Common Stock at an exercise price of $0.33
per share.
On June 9, 2000 the Company signed an Amendment to a License and Technology
Agreement dated September 4, 1998. Under the Amendment the Company was required
to, among other things, issue 128,571 shares of Common Stock to AccuMed
International, Inc. A fair value of $385,713 was recorded to equity to cover the
issued shares. Under the Amendment the Company has agreed to price protect the
value of these shares up to a maximum of $3.50 per share for a period of up to
60 days following the date on which the shares become freely tradable.
During 1999, the Company issued options to purchase 250,000 shares of Common
Stock, 70,000 of which were subsequently cancelled in 2000, to non-employees for
consulting services. The options vest over three years and have exercise prices
of $0.394 and $0.406 per share. The Company issued these options to consultants
as consideration for services that commenced during 1999 and will be completed
in 2001. During 2000, the Company issued additional options to purchase 20,000
shares of Common Stock to non-
9
10
employees for consulting services. These later options also vest over three
years and have an exercise price of $2.6675 per share. These options were issued
as consideration for services that commenced during 2000 and will be completed
during 2002. As the measurement date of all of these outstanding options had not
been determined at June 30, 2000 the value of these options will be determined
at the end of each interim period until the measurement date is determined.
Accordingly, a fair value of $700,000 was calculated at June 30, 2000 using the
Black-Scholes method. This value is charged to consulting expense over the term
of the consulting agreement. The amount of expense to be ultimately recognized
will vary depending on the market value of the Common Stock at the end of each
period. For the six-month period ended June 30, 2000 the Company recorded
$152,000 as consulting expense.
In January 2000 the Company issued options to purchase 25,000 shares of Common
Stock to a non-employee for consulting services. The options were for consulting
services completed as of the date of the grant. The options vested immediately
and have an exercise price of $0.921. The fair value of the options, as
calculated using the Black-Scholes method, was estimated at $23,000 at the date
of the grant. The Company recorded the entire $23,000 amount as compensation
expense for the three-month period ended March 31, 2000.
In August 1999, the Company awarded restricted shares of Common Stock to two
outside consultants in accordance with the provisions of the Plan. Each award of
50,000 shares vests over a period of time, ranging from the date of grant to
three years. The consultant must maintain the consulting relationship with the
Company, except in the case of change of control or termination by the Company
without cause, during the entire vesting period. The measurement date of these
shares had not been determined at June 30, 2000 and therefore the value of these
shares will be based on the market value of the Common Stock at the end of each
interim reporting period until the measurement date is determined. Accordingly,
a fair value of $350,000 was calculated at June 30, 2000 using the Black-Scholes
method. This value is charged to expense over the term of the consulting
agreement. For the six-month period ended June 30, 2000 the Company recorded
$95,933 as consulting expense.
In applying the Black-Scholes method, the Company has used an expected dividend
yield of zero, a risk-free interest rate of 5%, a volatility factor of 185% and
a fair value of the underlying common shares of $3.625 for options and
restricted stock issued to consultants and the closing market price on the date
of grant for warrants issued to consultants. The expected life equaled the term
of the options or restricted shares.
At June 30, 2000 and December 31, 1999, the Company had 450,000 stock
appreciation rights (SAR's) outstanding. These SAR's, issued in 1989, have an
exercise price of $0.30 and can be exercised through November 20, 2001. In
general, each SAR entitles the holder to receive upon exercise an amount equal
to the excess, if any, of the market value per share of Common Stock at the date
of exercise over the exercise price of the SAR, plus any dividends or
distributions per share made by the Company prior to the exercise date. In lieu
of making cash payments, the Company may elect to issue shares of Common Stock
on a one share for one SAR basis. The Company has recorded a compensation
expense in the amount of $1,265,625 for the six-months June 30, 2000 to reflect
the difference between the respective closing market prices of the Company's
common stock at June 30, 2000 and December 31, 1999 and the exercise price of
the SAR's.
10
11
Item 2 Management's Discussion and Analysis of Financial Condition and Results
of Operations
RESULTS OF OPERATIONS
OVERVIEW
See Note B to the Consolidated Financial Statements for background and
historical information on the Company. The Company is primarily engaged in the
design and development of new products to serve the market for cancer screening.
With the exception of the software products and services marketed by the
Company's wholly owned subsidiary, Samba Technologies, Sarl, all other products
have not as yet been introduced to the market for sale.
REVENUES
The Company's revenue of $541,000 for the six-month period ended June 30, 2000
compared to $542,000 for the six-month period ended June 30, 1999. Revenues for
both periods were derived entirely from the sale of Samba products. The average
exchange rate between the U.S. Dollar and the Euro (the currency to which
Samba's operating currency, the French Franc, is fixed) for the current
six-month period reflects a decline in the value of the Euro to the U.S. Dollar
of approximately 13% from the previous year's six-month period. This decline
reduced the translated value of Samba's revenue for the current six-month period
by approximately $69,000. The Company's revenue for the three-months ended June
30, 2000, amounting to $179,000, declined $52,000 from revenues of $231,000 for
the three-months ended June 30, 1999. Approximately 50% of the decline was the
result of the decrease in the exchange rate with the balance resulting from a
short-term delay in the completion of customer orders. Revenue for the current
year three-month period reflects a decline of approximately 50% compared to
revenue for the immediately preceding three-month period. This decline is the
result of the variability in the timing of contracts received and completed from
period to period.
COST AND EXPENSES
COST OF GOODS SOLD
Cost of goods sold for the six months ended June 30, 2000 amounted to $349,000
an increase of 12% over the $311,000 reported for the six-months ended June 30,
1999. Cost of goods sold for the three-months ended June 30, 2000 amounting to
$159,000 was approximately equal to the cost of goods sold as reported for the
three-month period ended June 30, 1999. The amounts for the current year's, six
and three-month, periods are also affected by the currency valuation issues
outlined under revenues. The costs for both periods were entirely related to
Samba products and services. The reductions in gross profit for the current, six
and three-month periods compared to the prior year periods, is the result of
changes in product mix of services and hardware on contracts completed during
the periods. Gross margin for the three-months ended June 30, 2000 declined to
11% from the 33% reported for the three-months ended March 31, 2000. This
decline is the result of changes in product mix for the quarter and lower
quarter revenues versus fixed costs.
RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses were $1,319,000 for the six-months ended June
30, 2000. These costs represent contracted development and consulting services,
manufacturing design services, contract research, and in-house development
personnel, laboratory expense, and research administration. R & D costs for the
six-months ended June 30, 1999 were $514,000. The increase of $805,000, or 157%,
represents increased development cost of the instrument and disposable
components of the Company's InPath System for cervical cancer screening. The
development ramp-up began in the third quarter of 1999 and has continued at a
pace intended to get the Company's products into clinical trials as soon as
possible. During the six-months ended June 30, 2000 the Company also recorded
non-cash R & D consulting
11
12
expense of $248,000 to reflect the current market value of options and
restricted stock granted to non-employee consultants during 1999. The options
and stock are related to services to be performed by the consultants over a
three-year period and the charge for the six-month period reflects the adjusted
amortization of their current value over the period
Research and development expenses for the three-months ended June 30, 2000 were
$513,000 representing an increase of 78% over the $289,000 reported for the
three-months ended June 30, 1999. This increase was the result of the ramp-up
development efforts previously described. The R & D expenses for the
three-months ended June 30, 2000 declined approximately $292,000 from similar
expenses for the three-months ended March 31, 2000. The primary reason for the
decline was the elimination of non-cash R & D expense during the current period
related to the above options and stock awards. Since the Common Stock market
value declined slightly between the end of the first quarter and the end of the
second quarter, no additional expense, in fact there was a slight reversal of
previous expense, was recorded for the quarter. In addition the termination of
certain consulting contracts and the cancellation of 70,000 options to purchase
Common Stock related to those contracts resulted in a reversal of previously
recorded non-cash R & D consulting expense of approximately $78,000.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
Selling, general and administrative expenses were $2,654,000 for the six-months
ended June 30, 2000, an increase of $1,631,000, or 159%, over the $1,023,000
reported for the six-months ended June 30, 1999. During the six-months ended
June 30, 2000 the Company recorded a non-cash compensation charge $1,265,000 to
reflect the value of outstanding SARs at June 30, 2000. The Company also
recorded an additional non-cash compensation charge of $23,000 to reflect the
fair value of options granted to a non-employee consultant for services already
completed. These non-cash charges were offset by the reclassification of
$250,000 of previously recorded royalty expense to prepaid royalties. The
reclassification was the result of the settlement of a dispute related to a
Patent and Technology License Agreement between the Company and AccuMed
International, Inc. These three items represent approximately 64% of the total
increase for the current six-month period. The balance of the increase reflects
the larger scale of operations of the Company during the period.
Selling, general and administrative expenses were $171,000 for the three-months
ended June 30, 2000, a decline of $388,000 from the $559,000 for the
three-months ended June 30, 1999. This decline was the net result of the
reclassification of $500,000 in previously recorded royalty expense to prepaid
royalties and a reduction of $254,000 in the previously recorded non-cash
compensation related to the value of outstanding SARs offset by an increase in
the overall scale of the operations of the Company. Selling, general, and
administrative expenses for the three-months ended June 30, 2000 declined
$2,312,000 from similar expenses for the three-months ended March 31, 2000. This
declined was primarily the result of a reduction in quarter-to-quarter non-cash
compensation expenses related to the value of SARs of $1,773,000 and the
reclassification of $500,000 in previously recorded royalty expense to prepaid
royalty.
OTHER INCOME AND EXPENSE
The Company incurred $30,000 and $31,000 in interest expense during each of the
six-month periods ended June 30, 2000 and 1999. During the six-month period
ended June 30, 2000 the Company earned interest income of approximately $27,000
from a note receivable.
The Company incurred $9,000 in interest expense for the three-months ended June
30, 2000 compared to $22,000 for the three-months ended June 30, 1999. The
reduction in interest expense reflects the conversion of outstanding 6% Notes
into Common Stock during the period. The Company earned $27,000 in interest
income from a note receivable during the 2000 period.
Interest expense for the three-months ended June 30, 2000 declined $12,000 from
the three-months ended March 31, 2000 primarily as the result of the conversion
of outstanding 6% Notes into Common Stock on April 28, 2000.
12
13
NET LOSS
The net loss for the six-months ended June 30, 2000 was $3,785,000, or $0.15 per
share, on 25,582,805 weighted average outstanding shares. The net loss for the
six-months ended June 30, 1999 was $1,338,000, or $0.11 per share, on 12,365,000
weighted average shares outstanding. The net loss for the three-months ended
June 30, 2000 was $646,000, or $0.02 per share on 29,865,088 weighted average
shares outstanding. The net loss for the three-months ended June 30, 1999 was
$795,000, or $0.06 per share on 12,638,750 shares outstanding. $1,536,000, or
41%, of the net loss increase in the 2000 six-month period is directly related
to the recording of non-cash compensation and consulting expenses related to
options, restricted stock, and outstanding SARs.
LIQUIDITY AND CAPITAL RESOURCES
The Company's primary cash requirements continue to be for research, development
and design expenses of its InPath System products and the conversion of those
designs through the process of clinical trials and manufacturing. At June 30,
2000 the Company had cash on hand of $56,000, an increase of $20,000 over cash
on hand at the previous year-end. The Company also held a note receivable due
July 31, 2000 amounting to $1,827,000, including accrued interest.
During January 2000, upon receipt of $565,000 the Company completed the sale of
Common Stock under a 1999 Private Placement Offering.
In January 2000, the Board of Directors authorized the Company to raise a
minimum of $5,000,000 in new equity, at a price of $1.50 per share. The Company
completed the Private Placement Offering on April 30, 2000 the Company having
received $5,375,000 in proceeds between February and April 2000.
On February 22, 2000 Azimuth Corporation exercised its right to convert the
$50,000 principal amount of a note plus $1,250 in accrued interest into shares
of Common Stock of the Company.
On April 10, 2000 the Company received $23,100 to exercise a warrant to purchase
Common Stock held by The Research Works.
As a result of the completion of the above-mentioned January Private Placement
Offering, $969,600 in principal of 6% Convertible Subordinated Notes Due 2000
plus $61,658 in accrued interest due thereon was automatically converted into
Common Stock of the Company.
During the six-months ended June 30, 2000 the Company's wholly owned subsidiary,
Samba Technologies, Sarl, reduced borrowings under its revolving credit by
$76,000.
On March 29, 2000, to resolve a dispute between InPath and AccuMed
International, Inc. (AccuMed) over a Patent and Technology License Agreement
(the "License") dated September 4, 1998, including related payments due
thereunder, the Company and AccuMed signed a Letter Agreement amending the
License. The original License, covering certain "Point of Care" related
applications, requires the payment of a minimum license fee of $500,000, against
which InPath had made payments of $400,000, and a 7% royalty rate. The original
license also requried InPath to make minimum royalty payments of $1,000,000 each
during the second and third years of the License, $1,500,000 each during the
fourth and fifth years, and $2,000,000 each year thereafter. The original
License cannot be cancelled by InPath, without the occurrence of a breach by
AccuMed, prior to the payment of $5,000,000 in royalties, or 5 years, whichever
comes first. InPath may elect to terminate its exclusivity under the original
License upon written notice to AccuMed at which time its obligation to make the
minimum required royalty payments cease. InPath would then only be obligated to
make royalty payments based on actual sales of products.
The new Amendment provides for the assignment of the License to the Company,
elimination of the minimum royalty payment schedule, while retaining the
$5,000,000 minimum royalty payment due over the 20-year life of the License, and
a reduction in the royalty rate to 4%. Upon signing the Letter Agreement to
amend the license, the Company paid AccuMed the remaining $100,000 minimum
license fee, and agreed to make additional
13
14
payments totaling $500,000, issue a $100,000 convertible promissory note due one
year from the date the License Amendment is signed, and issue 128,571 shares of
Common Stock to AccuMed. The note is convertible at AccuMed's option into Common
Stock, at a conversion price of $3.50 per share and the Company has agreed to
provide AccuMed with price protection equal to $3.50 per share on the 128,571
shares of Common Stock until a measurement date 60 days following the date on
which the shares are registered and freely tradable. The additional cash
payments are characterized as advanced non-refundable royalty payments. The
$100,000 principle amount of the note and the 128,571 shares of Common Stock to
a value of $450,000 are also characterized as advanced non- refundable royalty
payments.
The Amendment to the License was executed on June 9, 2000, the additional
$500,000 cash payment was made, the Company agreed to issue the $100,000 note
payable, and the 128,571 shares of Common Stock were issued. At the same time
the Company reclassified minimum royalty payments previously expensed, including
$250,000 during the three-months ended March 31, 2000 and $250,000 during the
final quarter of 1999, due under the License to prepaid royalties in accordance
with the terms of the License Amendment.
The Company has incurred significant net losses since its inception. The Company
expects that significant on-going operating expenditures will be necessary to
successfully implement its business plan and develop, manufacture and market its
products. These circumstances raise substantial doubt about the Company's
ability to implement its business plan and continue as a going concern unless
management obtains additional capital or acquires other sources of financing.
Management's plans include continuing efforts to obtain additional capital. The
Company has been successful in raising new equity and reducing debt through the
conversion of notes and accrued interest into Common Stock as outlined above.
However, there can be no assurance that the Company will continue to be
successful in raising capital should the need for such capital arise in the
future. If the Company is unable to obtain additional financing, should the need
arise, or generate profitable sales revenues, management may be required to
curtail the Company's product development and other activities and may be forced
to cease operations.
14
15
CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995.
Certain statements throughout this report are forward looking. These statements
are based on the Company's current expectations and involve many risks and
uncertainties. Some of these risks and uncertainties are factors that affect all
international businesses, while others are specific to the Company and the areas
of the medical products industry in which it operates.
The factors below in some cases have affected and could affect the Company's
actual results, causing results to differ, possibly materially, from those
expressed in this report's forward-looking statements. These factors include:
economic conditions; technological advances in the medical field; demand and
market acceptance risks for new and existing products, technologies, and
healthcare services; the impact of competitive products and pricing;
manufacturing capacity; new plant start-ups; U.S. and international regulatory,
trade, and tax policies; product development risks, including technological
difficulties; ability to enforce patents; and unforeseen foreign regulatory and
commercialization factors.
Currency fluctuations are also a significant variable for global companies,
especially fluctuations in local currencies where hedging opportunities are
unreasonably expensive or unavailable. If the value of the U.S. dollar
strengthens relative to the currencies of the countries in which the Company
markets or intends to market its products, the Company's ability to achieve
projected sales and net earnings in such countries could be adversely affected.
The Company believes that its expectations with regard to forward-looking
statements are based upon reasonable assumptions within the bounds of its
knowledge of its business and operations, but there can be no assurance that the
actual results or performance of the Company will conform to any future results
or performance expressed or implied by such forward-looking statements.
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The market risk inherent in the Company's financial statements is the potential
loss in fair value arising from adverse changes in interest rates. The Company
does not engage in any hedge transactions or use derivative financial
instruments to reduce its exposure to interest rate changes since all of the
Company's indebtedness is financed at fixed rates. At June 30, 2000, the
carrying amount of the Company's debt instruments approximated their fair value.
In addition, as of June 30, 2000, the Company was not exposed to any material
foreign-currency, commodity-price, equity-price or other type of market or price
risk. The Company's wholly owned subsidiary, Samba, conducts the majority of its
operations in Europe using EURO and local European currencies. At June 30, 2000
the Company has recorded a negative cumulative translation adjustment of
($132,000) reflecting the current valuation of the Company's investment in and
current account with Samba.
15
16
Part II. Other Information
Item 1 Legal Proceedings
None
Item 2 Changes in Securities
During the three-month period ended June 30, 2000, the Company sold 2,756,666
shares of Common Stock to several private investors for a total cash sales price
of $4,135,000. The shares were not registered under the Securities Act of 1933,
as amended, (the"Act') in reliance upon the exemption contained in Section 4(2)
of the Act and regulations promulgated under the Act. The Company did not engage
in any general solicitation or advertising in connection with the sale. The
private investors were "accredited investors" as defined under the Act and were
given access to the types of information required by Regulation D.
On April 10, 2000 the Company received proceeds of $23,100 as the result of the
exercise of a warrant to purchase 70,000 shares of Common Stock held by The
Research Works. The warrant shares were not registered under the Act in reliance
upon the exemption contained in Section 4(2) of the Act.
On April 28, 2000, all outstanding 6% Convertible Subordinated Notes Due 2000
totaling $969,600 in principal plus accrued interest due thereon of $61,658 were
automatically converted into 5,156,294 shares of Common Stock. The original
Notes, issued and the shares issued upon such conversion, were not registered
under the ACT, in reliance upon the exemption contained in Section 4(2) of the
Act.
Item 3 Defaults on Senior Securities
None
Item 4 Submission of Matters to Vote of Security Holders
The Company held its Annual Meeting of Stockholders on May 23, 2000. The
tabulation of the stockholders vote on each proposal presented for vote was as
follows:
Proposal 1: To elect five nominated directors:
Nominee In Favor Withheld
------- -------- --------
John Abeles, M.D. 19,571,614 17,000
Peter Gombrich 19,571,614 17,000
Alexander Milley 19,420,099 168,515
Denis O'Donnell, M.D. 19,571,614 17,000
Robert Shaw 18,581,665 1,006,949
Proposal 2: To approve Amendment No.1 to the Ampersand Medical
Corporation 1999 Equity Incentive Plan to increase the number of shares
of Common Stock allocated to the Plan from 2,000,000 shares to
3,000,000 shares:
For Against Abstain
--- ------- -------
19,531,904 7,495 49,215
16
17
Proposal 3: Ratification of the appointment of Ernst & Young LLP as
independent auditors for the Company for the year ended December 31,
2000.
For Against Abstain
--- ------- -------
19,571,966 Zero 648
Item 5 Other Information
None
Item 6 Exhibits and Reports on Form 8-K
Exhibits The following exhibits are filed herewith:
Exhibit Number Description
27 Financial Data Schedule
Reports on Form 8-K
None
17
18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Ampersand Medical Corporation
/s/ Leonard R. Prange
--------------------------------
Leonard R. Prange
President, Chief Operating Officer, Chief
Financial Officer and Secretary
Principal Accounting Officer
Date: August 14, 2000
---------------
18